Trade Names:Diar-aid- Tablets 2 mg
Trade Names:Imodium- Capsules 2 mg
Trade Names:Imodium A-D- Tablets 2 mg- Liquid 1 mg/5 mL
Trade Names:Kaopectate II Caplets- Tablets 2 mg
Trade Names:Neo-Diaral- Capsules 2 mg
Trade Names:Pepto Diarrhea Control- Liquid 1 mg/ mLApo-Loperamide (Canada)Riva-Loperamide (Canada)Sandoz Loperamide (Canada)
Slows intestinal motility, affects water and electrolyte movement through intestine, inhibits peristalsis, reduces daily fecal volume, increases viscosity and bulk density of stool, diminishes loss of fluid and electrolytes.
T max is 5 h (capsule) and 2.5 h (liquid). Bioavailability is 40%.
Apparent t ½ is 10.8 h (9.1 to 14.4 h). 25% is excreted unchanged in the feces; 1.3% is excreted in the urine unchanged and conjugated.
Control and symptomatic relief of acute nonspecific or chronic diarrhea; reduction in volume of ileostomy output.
Pseudomembranous colitis caused by antibiotic use; acute diarrhea associated with organisms that penetrate intestinal wall (eg, toxigenic Escherichia coli , Salmonella , Shigella ); conditions in which constipation should be avoided; bloody diarrhea; fever; acute ulcerative colitis (potential for toxic megacolon).
PO 4 mg followed by 2 mg after each unformed stool, not to exceed 16 mg/24 h.Children 8 to 12 yr of age (greater than 30 kg)
2 mg 3 times daily.Children 6 to 8 yr of age (20 to 30 kg)
2 mg twice daily.Children 2 to 5 yr of age (13 to 20 kg) First day
1 mg 3 times daily. May decrease to adjust for nutritional and hydration status after 24 h; usually 0.1 mg/kg after each loose stool but do not exceed total first day dosing recommendations on any day.Chronic DiarrheaAdults
PO 4 to 8 mg every day or twice daily.
Store at room temperature.
None well documented.
None well documented.
Fatigue; drowsiness; dizziness.
Abdominal pain; distention or discomfort; constipation; nausea; vomiting; dry mouth.
Category B .
Not recommended for children less than 2 yr of age. Use with caution in young children.
Hepatic coma may be precipitated in patients with advanced hepatorenal disease or hepatic dysfunction.
Agents that inhibit intestinal motility or delay intestinal transit time may induce toxic megacolon. Discontinue if abdominal distention or other untoward symptoms occur.
Constipation, CNS depression, GI irritation.
Copyright © 2009 Wolters Kluwer Health.